CG MedTech Announces 5:1 Stock Reverse Split to Stabilize Share Price, No Change in Market Cap
CG MedTech has decided on a 5:1 reverse stock split effective September 12, 2026, consolidating every 5 existing shares into 1 new share.
The total outstanding shares will decrease from 103,259,036 to 20,651,807, with the par value adjusting from 500 KRW to 2,500 KRW per share.
The purpose is to stabilize the stock price and enhance corporate value by maintaining an appropriate number of shares in circulation, with no change in market capitalization or capital reduction.
The proposal requires approval at the extraordinary shareholders' meeting on August 11, 2026, and trading will be suspended from September 10 to October 6, 2026.
Fractional shares will be paid in cash based on the closing price on the listing date, and the board resolution was passed with full attendance of two outside directors.
[AI Summary]The 5:1 reverse split reduces share count without altering market cap, offering a neutral structural adjustment. Investors should monitor the shareholder meeting approval and the trading suspension period.